Recent Updates
Recently added Catalysts
NAUT Positive Sentiment

Insights from Iterative Mapping of tau proteoforms – bioRxiv preprint round up

Key Takeaway: Nautilus Biotechnology's recent preprint discusses the use of Iterative Mapping to analyze tau proteoforms, which are linked to cognitive decline in Alzheimer's disease. The study highlights the method's ability to provide single-molecule resolution and its potential to reveal new insights into disease mechanisms. Preliminary data suggests a connection between specific tau proteoforms and disease severity, paving the way for advancements in drug and biomarker development.
Price reaction · baseline $0.7508 (2025-08-05 close) · hit after-hours · 1 other NAUT headline(s) in the window, move may be shared
day 0 close · peak
+4.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Innovative approach to proteoform analysis with single-molecule resolution.
  • Potential to uncover novel biology and drug targets related to tau proteoforms.
  • Demonstrated association of certain tau proteoforms with disease severity.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~29 mo
Minimal dilution risk
Lead asset
MDMA
Phase 2 · Post-Traumatic Stress Disorder

Full Press Release Details

Applications of Proteomics
Nautilus Biotechnology
August 5, 2025
Using Iterative Mapping, the Nautilus Proteome Analysis Platform enables researchers to quantify proteoforms with single-molecule resolution. In our recent preprint, we cover the application of this method to the large-scale single-molecule analysis of tau proteoforms . Tau is associated with cognitive decline in Alzheimer’s disease and related dementias, but we do not know which of the many possible functional forms of tau (tau proteoforms ) contribute to disease. In our preprint, we share data demonstrating the unparalleled benefits of Iterative Mapping of proteoforms as well as preliminary evidence for the association of certain tau proteoforms with disease severity.
We recently covered the key findings from the preprint in the four blog posts highlighted below. For more details:
• Read our full pre-print.
• Explore the quantitative benefits of Iterative Mapping of proteoforms in our Tech Note.
• Read our App Note discussing tau proteoform analysis.
• Watch our on-demand webinar covering this data.
Join the Iterative Mapping Early Access Program to be one the first to use the Nautilus Platform in your research.

Iterative Mapping of proteoforms may reveal novel biology and new drug targets

Here, we cover metrics demonstrating the benefits of Iterative Mapping on the Nautilus Proteome Analysis Platform, share why tau proteoforms are great examplars for the power of proteoform analysis, and discuss how knowledge of proteoforms can advance drug and biomarker development.
Find the full post here.

Iterative Mapping of proteoforms may reveal novel biology and new drug targets

In this blog post, we share how Iterative Mapping of proteoforms enables researchers to achieve proteoform group resolution in a way that is readily scalable and adaptable with additional probes. This level of proteoform resolution provides researchers with unique views of the proteome and actionable information about biology that cannot be obtained with most other technologies. We’ll walk through a theoretical example demonstrating how our technology is different and then provide a sneak peek at data demonstrating the power of our method before diving into additional data in the next two posts in this series.
Find the full post here.

Iterative Mapping provides in-depth views of proteoform groups

There are many open questions about proteoforms. They are the functional variants of proteins found in biological systems. Yet until now, the tools available to identify and measure them have been limited. Thus, we have minimal understanding of the scope of proteoform complexity in any given biological system. This post covers how we used Iterative Mapping to chart the complexity of the tau proteoform landscape by answering the following questions:
• How many phosphorylations are found on individual tau molecules?
• What combinations of tau phosphorylation are found on tau molecules?
• What mixtures of tau proteoforms are present?
• Is there timing and coordination underlying the creation of tau proteoforms?
Find the full post here.

Proteoforms are not random – evidence for order in the creation of proteoforms

In the final post in this series, we dive into evidence suggesting that the specific, multiply modified proteoforms found in biological systems associate with important phenotypes. We further discuss how exploring associations between proteoforms and disease severity may accelerate research and enable the development of new precision medicines.
Read the full post here.

Proteoform profiles may differentiate disease phenotypes

Share this Article
Stay up-to-date on all things Nautilus
World-class articles, delivered weekly
MORE ARTICLES
Proteomics applications in medicine, basic biology, and beyond
Proteomics is being applied in many biological fields to unlock new discoveries and drive scientific advances.
Read more
White paper series: The proteomics revolution
This post contains white papers describing how developments in proteomics - led by the Nautilus platform - will improve healthcare.
Read more
Targeting healthcare disparities through the proteomics revolution (Part 1)
Learn how biases have led to inequities in healthcare and how researchers can rectify those inequities with better data.
Read more
Stay up-to-date on all things Nautilus

Subscribe to our Newsletter

Frequently Asked Questions

What is the purpose of Iterative Mapping?

Iterative Mapping enables researchers to quantify proteoforms with single-molecule resolution.

How are tau proteoforms related to Alzheimer's?

Tau proteoforms are associated with cognitive decline in Alzheimer's disease and related dementias.

What benefits does the Nautilus platform provide?

The Nautilus platform offers unique insights into proteoform complexity and potential drug targets.

What findings were shared in the preprint?

The preprint discusses the association of certain tau proteoforms with disease severity.

Last updated: Aug 5, 2025